|
Breast cancer subtypes linked to survival from secondary brain tumors
February 28, 2008Screening breast cancers for three receptors could help doctors predict the likely survival of patients with brain metastases. A study published in the open access journal Breast Cancer Research shows that patients with tumours that are negative for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor-2 (HER2) or that are HER2+/ER- appear to be most at risk from developing brain metastases. Survival is also correlated to the triple receptor status.
This is the first time that researchers have documented a possible link between breast cancer subtypes and the incidence and prognosis of brain metastases, which occur in up to one third of metastatic breast cancer patients.
A team from the National Cancer Centre in the Republic of Korea analysed data from 126 patients with brain metastases from a pool of 805 patients diagnosed with metastatic breast cancer and treated at the Centre. The presence or absence of ER, PR and HER2 were tested by immunohistochemical staining and/or fluorescent in situ hybridisation.
More than half of the patients with early (non-metastatic) breast cancer were of the luminal A subtype (ER or PR+ and HER2-). The proportion of patients with HER2+/ER- or triple-negative tumours was significantly higher among patients with brain metastases compared to the early breast cancer population, suggesting that these latter two subtypes were associated with the development of brain metastases.
The analysis also showed a correlation between the survival of patients and their triple receptor subtypes following the diagnosis of brain metastases, the survival time of which is just 3 - 6 months. Patients with luminal A (4.0 months) and triple-negative tumours (3.4 months) had a similar shorter survival time compared with luminal B (ER or PR+ and HER2+; 9.2 months) and HER2+/ER- (5.0 months) tumours.
Patients with HER2-positive tumours experienced a significant survival benefit if they were treated with trastuzumab after their brain metastases were diagnosed.
"Our study suggests that the triple-negative subtype should be added to the list of risk factors for developing BM," remarks Jungsil Ro, the study's corresponding author. "Approximately 10-15% of all breast cancer presents this phenotype; they have a poor prognosis and are more likely to develop brain metastases. Triple receptor status can also help to predict survival even after brain metastases have been diagnosed. We now need to develop ways to screen for these subtypes and find the best ways to manage patients with this more aggressive phenotype."
BioMed Central
More than half of the patients with early (non-metastatic) breast cancer were of the luminal A subtype (ER or PR+ and HER2-). The proportion of patients with HER2+/ER- or triple-negative tumours was significantly higher among patients with brain metastases compared to the early breast cancer population, suggesting that these latter two subtypes were associated with the development of brain metastases.
The analysis also showed a correlation between the survival of patients and their triple receptor subtypes following the diagnosis of brain metastases, the survival time of which is just 3 - 6 months. Patients with luminal A (4.0 months) and triple-negative tumours (3.4 months) had a similar shorter survival time compared with luminal B (ER or PR+ and HER2+; 9.2 months) and HER2+/ER- (5.0 months) tumours.
Patients with HER2-positive tumours experienced a significant survival benefit if they were treated with trastuzumab after their brain metastases were diagnosed.
"Our study suggests that the triple-negative subtype should be added to the list of risk factors for developing BM," remarks Jungsil Ro, the study's corresponding author. "Approximately 10-15% of all breast cancer presents this phenotype; they have a poor prognosis and are more likely to develop brain metastases. Triple receptor status can also help to predict survival even after brain metastases have been diagnosed. We now need to develop ways to screen for these subtypes and find the best ways to manage patients with this more aggressive phenotype."
BioMed Central
Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
Prophylactic cranial irradiation after chemotherapy significantly reduces the risk of brain metastasis and doubles one-year survival in small-cell lung cancer (SCLC).
Systemic treatment before surgery for kidney cancer prolongs patients' survival
Preliminary results from a phase II clinical trial have provided the first evidence that treating people with kidney cancer with bevacizumab and erlotinib before surgery is safe, effective and may prolong patients' survival.
Study compares treatment options for patients with brain metastases
Adding whole-brain radiation therapy to highly-focused radiation therapy does not improve survival for patients with cancer and brain metastases, but it may reduce the likelihood of the recurrence of brain metastases.
Treating multiple brain tumors with radiosurgery results in improved survival
Treating four or more brain tumors in a single radiosurgery session resulted in improved survival compared to whole brain radiation therapy alone.
First results from novel anti-angiogenic drug trial in patients
"Surprisingly effective" says French research team Frankfurt, Germany: A new drug that targets tumour blood vessels has produced a surprisingly effective response in its first patient study - shrinking the tumours in a number of patients treated so far, according to researchers carrying out the study at the Institut Gustave Roussy in Villejuif, France. The drug, SU011248[1], which is given in capsule form, is a signal transduction inhibitor designed to act against several abnormally behaving enzymes along the cellular signalling pathway.[2] Results of the first Phase I study were presented today (Wednesday 20 November) at the EORTC-NCI-AACR[3] Symposium on Molecular Targets and Cancer Thera
More Brain Metastases News Articles
 | Intracranial Metastases: Current Management Strategies |
 | Brain Metastases (Cancer Treatment and Research) |
| Brain metastases (Current problems in cancer) by Phillip Davey | |
| Management strategies for patients with brain metastases: has radiosurgery made a difference?(Original Article): An article from: Southern Medical Journal by Ajay Jawahar, Federico Ampil, Christina Wielbaecher, Golda H. Hartman, John H. Zhang, Anil Nanda |
| © 2008 BrightSurf.com |